AlloVir

AlloVir, based in Waltham, Massachusetts, focuses on pioneering developments in allogeneic, virus-specific T cell (VST) therapies. These therapies are aimed at treating and preventing a range of viral infections in patients with compromised immune systems. The company’s product pipeline includes several promising candidates such as Posoleucel, ALVR106, and ALVR107, each targeting different viral pathogens. Posoleucel is designed to combat six major viruses, including adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. ALVR106 targets respiratory and flu-related viruses such as human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus. ALVR107, currently in preclinical and IND-enabling studies, is focused on treating and potentially curing chronic hepatitis B virus infections. AlloVir utilizes a proprietary platform to develop these off-the-shelf VSTs, aiming to restore immunity in patients with T cell deficiencies.